Blue toe syndrome, severe haemophilia A and emicizumab-Reference-Cited by-同舟云学术

Blue toe syndrome, severe haemophilia A and emicizumab

Published:2023-10-23 Issue:1 Volume:30 Page:241-244
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Cardoso Patrícia Santos Resende¹²^ORCID,da Silva Camila Beatriz Pereira Gomes³,de Abreu Eliabe Silva³,Oliveira Andrea Gonçalves²,Pereira Isabel Figueiredo de Magalhães⁴,Navarro Túlio Pinho⁵,Rezende Suely Meireles⁶^ORCID

Affiliation:

1. Hematology and Oncology Unit, University Hospital Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil

2. Hematology HEMOMINAS Foundation Belo Horizonte Minas Gerais Brazil

3. Haemostasis and Thrombosis Study Group, Faculty of Medicine Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil

4. Vascular Surgery University Hospital, Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil

5. Department of Surgery, Faculty of Medicine Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil

6. Department of Internal Medicine, Faculty of Medicine Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14893

Reference10 articles.

1. As bases moleculares da hemofilia A

2. Advancement in the treatment of haemophilia

3. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

4. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

5. Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-04-27